Many interventional trials have demonstrated
|
|
- Erica Leonard
- 6 years ago
- Views:
Transcription
1 AJH 1998;11: Short-Term Effects of Withdrawing Angiotensin Converting Enzyme Inhibitor Therapy on Home Self-Measured Blood Pressure in Hypertensive Patients Laurent Vaur, Guillaume Bobrie, Claire Dutrey-Dupagne, Isabelle Dubroca, Bernard Vaisse, Michel Bouvier d Yvoire, François Elkik, Gilles Chatellier, and Joël Menard The aim of this study was to compare blood pressure rise after interruption of two angiotensin converting enzyme (ACE) inhibitors in hypertensive patients. After a 2-week placebo run-in period, hypertensive patients were treated with either trandolapril 2 mg once daily or perindopril 4 mg once daily for 4 weeks in a double-blind design. A placebo was then administered for 1 week. Three periods of 1-week home self-measured blood pressure (SMBP) were programmed: end of placebo run-in period, end of treatment period, and final withdrawal placebo period. Every day, three consecutive measurements were requested both in the evening and in the morning. Individual reversion to baseline BP level was studied in the subgroup of patients responding to therapy (evening diastolic SMBP decrease >6 mm Hg). The ratio (R) of mean post-drug DBP lowering (residual effect) over evening on-drug DBP lowering (full effect) was used to study reversion to baseline. Patients exhibiting a lower value than the median of this ratio were called Reverters, whereas others were called Nonreverters. One hundred-nineteen patients entered the analysis. During the treatment period, mean SMBP decreased significantly, from / 97 7mmHgto139 15/91 9 mm Hg (all P <.001). The on-drug BP level was similar in the evening in the two treatment groups. However, both systolic and diastolic morning SMBP levels were significantly lower in the trandolapril group. After drug discontinuation, the mean BP level significantly rose to /94 9 mm Hg (all P.01) but remained lower than the baseline BP values (P.003 for SBP and P.002 for DBP). The post-drug BP level was significantly lower in the trandolapril group than in the perindopril group. Seventy-four patients were responders to therapy. In this subgroup, the median of the R ratio used to analyze reversion to baseline after drug discontinuation was 44%. Nonreverters were characterized by a sustained on-drug BP decrease, compared to Reverters. We therefore conclude that ACE inhibitor treatment withdrawal is accompanied by a rapid rise in BP (within 48 h), followed by a 5-day BP plateau that is lower than the initial level. Reverters to baseline after drug discontinuation were more likely to be insufficiently controlled during therapy, particularly in the morning. The longer duration of action of trandolapril was associated with a lower BP level during both the morning during the active treatment phase and the 1-week posttreatment phase. Am J Hypertens 1998;11: American Journal of Hypertension, Ltd. KEY WORDS: Home self-measured blood pressure, treatment withdrawal, angiotensin converting enzyme inhibitor therapy. From the Laboratoires Roussel, Direction Médicale, Paris; Service de Néphrologie et Hypertension Artérielle, Centre Hospitalier, Vannes; HMR France, Paris; Centre Hospitalier Régional Universitaire La Timone, Marseille; and Centre d Investigations Cliniques, Hôpital Broussais, Paris, France. Address correspondence and reprint requests to Doctor L. Vaur, Laboratoires Roussel, Direction Médicale, Tour Roussel-Hoechst, 1 Terrasse Bellini, Paris-La Défense, France. Many interventional trials have demonstrated that antihypertensive agents significantly reduce long-term morbidity and mortality in mild to severe hypertensive patients. 1 3 The reduction in the incidence of stroke has been shown to be the most striking and 1998 by the American Journal of Hypertension, Ltd /98/$19.00 Published by Elsevier Science, Inc. PII S (97)
2 166 VAUR ET AL AJH FEBRUARY 1998 VOL. 11, NO. 2 constant benefit. The reduction in the incidence of coronary events was lower than expected, though highly significant. These benefits were proportional to the extent of blood pressure lowering and related to the duration of the treatment period. They were obtained in large-scale trials testing diuretics or -blockers v placebo. Although not demonstrated, it is suggested that the use of other drug classes may lead to at least the same benefits. 4,5 This is the main reason most hypertensive patients who begin receiving medication should expect to be treated on a life-long basis. However, discontinuation of therapy may occur under two circumstances. First, the practitioner may decide to interrupt the medication. This is supported by the hypothesis of resetting the BP control mechanism. Some authors assumed that the carotid sinus barostat mechanism, having been reset at a higher level during periods of hypertension, might be reset at a lower level if BP was consistently reduced. 6 If treatment led to resetting of baroreceptors or any other BP control mechanism, it should be possible to interrupt medication in the expectation of a remission period. Discontinuous rather than continuous treatment may then be possible for at least some patients. Treatment interruption might also identify people in whom BP will remain low for other reasons and for whom further treatment is unnecessary. 6 8 Discontinuation of therapy may also occur because of patient s behavior. 9,10 It has long been recognized that patients often do not wholly comply with the instructions for use of their medication. Protracted intervals between doses may occur, particularly when dosing frequency is greater than once daily. This commonly occurs in the form of drug holidays, where doses are omitted for 1 or more days. 10,11 Withdrawal of antihypertensive therapy and drug holidays raise the question of how and when BP rises after interruption of therapy. 12 The present study was conducted to answer this question by analyzing the course of BP during the week after discontinuation of two ACE inhibitors in hypertensive patients. Home self-measured blood pressure (SMBP) was chosen as the BP evaluation method because standardized measurements repeated during several consecutive days were needed. METHODS Study Design After a 2-week single-blind placebo run-in period, patients entered a 4-week double-blind active treatment period, where they were randomized to receive either 2 mg trandolapril once daily or 4 mg perindopril once daily. This phase was followed by a 1-week single-blind placebo period. Patients were instructed to take their medication at 8:00 am. Compliance and exact time of drug intake were checked by electronic pill-boxes (MEMS; Aprex Ltd, Fremont, CA). The protocol was approved by the Comité Consultatif de Protection des Personnes se Prêtant à la Recherche Biomédicale of Rennes, France. Blood Pressure Measurements Office BP was measured at the end of the placebo run-in phase. Three consecutive measurements were performed by the physician using a mercury sphygmomanometer with the patient in the sitting position after a 5-min rest. The mean of these three measurements was taken for consideration for inclusion of the patient in the study. Home self-measurement of blood pressure (SMBP) was performed during the last week of the placebo run-in period, the last week of the active treatment period, and the week of the placebo post-treatment period. The weeks of SMBP of periods 2 and 3 were consecutive. Every day, a series of three consecutive measurements was requested in the morning before drug intake (8:00 am) and repeated in the evening (8:00 pm). Measurements were performed in the sitting position, after a 5-min rest, using the A&D UA 751 device (A&D Enginnering, Milpitas, CA), which is a printer-equipped, semiautomatic, digitized device based on the oscillometric method. It has been validated previously by comparison to a random-zero mercury sphygmomanometer. 13 Each BP value was printed on a ticket with the date and exact time of measurement. Patients Male and female patients aged years with mild to moderate essential hypertension were eligible to enter the study. At the end of the 2-week placebo run-in period, office diastolic blood pressure (DBP) had to be confirmed in the range of mm Hg and the median of home self-measured DBP had to be greater than 85 mm Hg. The main exclusion criteria were any serious chronic disease, known hypersensibility or contraindication to ACE inhibitors, and obese arm, impairing the quality of SMBP. Any antihypertensive treatments other than the medications studied were not allowed during the study. Self-Measurement Data Management The first day of the placebo run-in period and the treatment period were considered as training and the corresponding values were not analyzed. The theoretical number of available measurements was therefore 36 during the baseline period (18 in the morning and 18 in the evening), 39 during the active treatment period (21 in the morning and 18 in the evening), and 33 during the post-treatment period (15 in the morning and 18 in the evening). Aberrant values were deleted according to the following rules: DBP 40 or DBP 150 mm Hg, SBP 60 or 250 mm Hg, pulse pressure 10 mm Hg when SBP 110 mm Hg; measurements performed
3 AJH FEBRUARY 1998 VOL. 11, NO. 2 SMBP AND ACE INHIBITOR WITHDRAWAL 167 outside the predefined morning and evening times (4:00 am to noon for morning SMBP or 4:00 pm to midnight for evening SMBP); or measurements performed outside the predefined intervals (12 4 h after drug intake for evening SMBP or 24 4 h for morning SMBP). The data of patients having at least six morning and six evening validated measurements for each of the three periods were analyzed. Individual home BP was defined for each period as the mean of all available values. The mean of morning measurements was considered for morning SMBP, the mean of evening measurements for evening SMBP, and the mean of all measurements for global SMBP. Analysis of BP Rise After Drug Discontinuation Individual reversion to baseline BP level was studied in the subgroup of patients responding to therapy. As previously described, patients were defined as responders when evening diastolic SMBP decreased by at least 6 mm Hg during the treatment phase, compared to baseline. 14 The ratio (R) of mean post-drug DBP lowering over evening on-drug DBP lowering was used to study the degree of reversion of each patient. Patients exhibiting a lower value than the median of the R ratio were called Reverters to baseline BP levels. Patients with higher value were called Non- Reverters. Characteristics of Reverters and Nonreverters were compared. Statistical Analysis Data are summarized as means standard deviation (SD). The difference between two qualitative variables was tested by the 2 test. The difference between two quantitative variables was tested by the Student s paired or unpaired t test, as appropriate. Analyses of covariance were performed to adjust either on-drug or post-treatment SMBP to baseline SMBP. A P.05 was considered significant. Calculations were performed using the SAS statistical package (SAS institute Inc, Cary, NC). RESULTS Baseline Characteristics of Patients Of the 152 patients entering the study, 33 were excluded from the analysis because of either major protocol deviations (16 patients) or failure to achieve the required minimum number of valid BP self measurements (17 patients). The remaining 119 patients were included in the statistical evaluation. There were 58 men and 61 women, aged years. At the end of the 2-week placebo run-in period, mean casual blood pressure was mm Hg for SBP and 103 6mmHgfor DBP. During the same period, mean home self-measured blood pressure was mm Hg for SBP and 97 7 mm Hg for DBP. The average number of home BP measurements was 34 3 during the placebo run-in period, 35 5 during the treatment period, and 31 4 during the post-treatment period. Morning SMBP occured at 7:53 0:59 am and evening SMBP at 7:50 1:07 pm. There were 62 patients in the perindopril group and 57 patients in the trandolapril group. The groups were well matched with regard to age, gender, weight, casual blood pressure, and home blood pressure upon entry to the study; indeed, no statistical differences between the groups were observed. Compliance assessed by electronic pill-boxes was over 80% in all the 119 patients entering the analysis. Mean compliance was % in the perindopril group and % in the trandolapril group. Drug intake occured at 8:20 1:37 am in the perindopril group and at 8:39 1:39 am in the trandolapril group. Effects on BP Course in the Overall Population Figure 1 and Table 1 refer to home BP levels during the three SMBP periods of the study in the overall population. During the treatment period, the average BP level was mm Hg for SBP and 91 9mmHgfor DBP. The BP level adjusted for baseline was lower in the trandolapril group (137 9 mm Hg/90 6mm Hg) than in the perindopril group (141 9mmHg/ 92 6 mm Hg) (Table 2). The difference was statistically significant only for SBP (P.04). As shown in Table 2, the difference in BP level between the two treatment groups reached statistical significance in the morning but not in the evening. After drug discontinuation the mean BP rose consistently for 2 days and then was stable during the following 4 days. The average BP level during the post-treatment phase was mm Hg for SBP and 94 9 mm Hg for DBP. These values were significantly higher than the mean on-drug BP levels (P.01 for both SBP and DBP) but lower than the baseline BP levels (P.003 for SBP and.002 for DBP). The adjusted BP level during the post-treatment phase was lower in the trandolapril group (142 9/93 5 mm Hg) than in the perindopril group (146 9mm Hg/95 5 mm Hg). There was a statistical difference between the two groups for both SBP (P.007) and DBP (P.05). Blood Pressure Rise After Drug Discontinuation in Responder Patients: Reverters v Nonreverters Seventy-four of the 119 patients were responders to therapy. The distribution of the ratio (R) of mean post-drug DBP lowering over evening on-drug DBP lowering is shown in Figure 2. Its median was 44%. Residual BP lowering of Reverters was close to zero; their median R ratio was 11% for SBP and 15% for DBP. In the Nonreverter group, BP lowering was consistently sustained despite withdrawing therapy; their median R ratio was 66% for SBP and 75% for DBP (Table 3). The BP rise after drug discontinuation in Reverters
4 168 VAUR ET AL AJH FEBRUARY 1998 VOL. 11, NO. 2 FIGURE 1. Home self-measured blood pressure (SMBP) levels during the three SMBP periods of the study (n 119). D0, first intake of active drug; D28, last intake of active drug. The first plot of each day corresponds to the mean morning SMBP; the second plot of each day corresponds to the mean evening SMBP. and Nonreverters is shown in Figure 3. The zero line corresponds to the baseline SMBP level. The plots represent the difference between this level and each post-treatment SMBP evaluation over time. They fit well with an exponential function whose general formula is: y y 0 (y y 0 )(1 e t ) where y 0 is the difference between baseline SMBP and last evening on-drug SMBP, y the plateau level, and the time constant. The resulting equations for Reverters and Nonreverters are given in Figure 3. The plateau level (y ) is close to mean baseline SMBP level in Reverters (1.4 mm Hg for SBP and 0.5 mm Hg for DBP), whereas it is consistently lower in Nonreverters (12.8 mm Hg for SBP and 8.4 mm Hg for DBP). Six days after withdrawal, the proportion of therapeutic effect (y /y 0 ) still present was 9% (SBP) and 5% (DBP) in Reverters v 55% (SBP) and 59% (DBP) in Nonreverters. Characteristics of Reverters and Nonreverters are depicted in Table 2. The differences in residual effects between Reverters and Nonreverters are summarized. As shown, these differences seem to be linked to the extent of on-drug BP lowering, particularly in the morning. TABLE 1. HOME BP COURSE OVER THE THREE PERIODS Baseline Period (SMBP [mm Hg]) SMBP (mm Hg) Drug Period PvBaseline Placebo PostTreatment Period SMBP (mm Hg) PvBaseline SBP Morning Evening Global DBP Morning Evening Global Abbreviations: SMBP, home self-measured blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure.
5 AJH FEBRUARY 1998 VOL. 11, NO. 2 SMBP AND ACE INHIBITOR WITHDRAWAL 169 TABLE 2. BASELINE AND ON-DRUG HOME SMBP IN THE TWO TREATMENT GROUPS Baseline SMBP Unadjusted On-Drug SMBP On-Drug SMBP Adjusted for Baseline SMBP P Group T Group P P Group T Group P P Group T Group P Morning SBP NS DBP NS Evening SBP NS NS NS DBP NS NS NS Mean SBP NS NS DBP NS NS NS Abbreviations: SMBP, home self-measured blood pressure; T, trandolapril; P, perindopril; SBP, systolic blood pressure; DBP, diastolic blood pressure. Blood Pressure Rise After Drug Discontinuation in Responder Patients: Trandolapril v Perindopril After drug discontinuation in responder patients, the residual SBP/DBP lowering was greater in the trandolapril group ( / mm Hg) than in the perindopril group ( / mm Hg). These differences were statistically significant for both SBP (P.01) and DBP (P.04). The BP rise after discontinuation of either drug has also been modeled, as shown in Figure 4. The plateau level (y ) is closer to the mean baseline SMBP level in the perindopril group (3.0 mm Hg for SBP and 1.9 mm Hg for DBP) than in the trandolapril group (7.5 mm Hg for SBP and 4.0 mm Hg for DBP). The proportion of therapeutic effect (y /y 0 ) still present 6 days after drug discontinuation was 23% (for both SBP and DBP) in the perindopril group v 49% (SBP) and 45% (DBP) in the trandolapril group. Characteristics of the two groups are depicted in Table 4. As shown, a significant difference in BP lowering was also present during therapy. In the evening, 12 h after dosing, the difference between the two groups was mild and only significant for DBP lowering (P.05). In the morning, 24 h after dosing, the difference was pronounced and significant for both SBP (P.03) and DBP (P.01). DISCUSSION Many studies have been designed to examine the long-term outcome among patients who stopped tak- FIGURE 2. Classification of Reverters and Nonreverters according to the individual degree of reversion to baseline BP levels. The R ratio is defined by the ratio of residual BP lowering (mean baseline SMBP level mean posttreatment BP level) over evening on-drug BP lowering.
6 170 VAUR ET AL AJH FEBRUARY 1998 VOL. 11, NO. 2 TABLE 3. CHARACTERISTICS OF REVERTERS AND NONREVERTERS AMONG RESPONDER PATIENTS Reverters (n 37) Nonreverters (n 37) P Residual effect after drug discontinuation Residual SBP lowering* (mm Hg) NA R ratio for SBP (median in %) y (mm Hg) Residual DBP lowering* (mm Hg) NA R ratio for DBP (median in %) y (mm Hg) Explanatory variables Age (years) NS Male gender (%) NS Patients receiving perindopril (%) NS Baseline SBP/DBP (mm Hg) / /97 6 NS On-drug evening SBP/DBP lowering (mm Hg) 17 9/ /12 4 NS On-drug morning SBP/DBP lowering (mm Hg) 7 9/ / /.002 On-drug global SBP/DBP lowering (mm Hg) 12 8/ / /.02 Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; NA, not applicable (the statistical comparison would be incorrect as the two groups are issued from the same truncated sample); NS, not significant. * Residual BP lowering, difference between mean baseline BP level and mean post-treatment BP level. R ratio, ratio of residual BP lowering over evening on-drug BP lowering. y, plateau level assessed by exponential modeling. ing chronic antihypertensive medication and were normotensive at the time of such cessation. 6,7,8,15 In these studies, the observation period lasted from 1 to 20 years (in the Framingham study 8 ) and casual BP measurements were taken every 1 to 6 months. They showed that the proportion of subjects remaining in initial remission ranged from 20% to 80% at 1 year. This proportion was then approximately halved every 2 years and no remission that exceeded 14 years was observed. One might consider that long-term remissions appear surprisingly frequent. In fact, these figures are FIGURE 3. Evolution of BP in responders after treatment discontinuation, in Reverters v Nonreverters. Formulas of exponential functions are Reverters: y (1 exp ( t)); Nonreverters: y (1 exp ( t)).
7 AJH FEBRUARY 1998 VOL. 11, NO. 2 SMBP AND ACE INHIBITOR WITHDRAWAL 171 FIGURE 4. Evaluation of BP in responders after treatment discontinuation, in trandolapril v perindopril. Formulas of exponential functions are trandolapril: y (1 exp ( t)); perindopril: y (1 exp ( t)). partly explained both by a regression to the mean phenomenon and by errors in the initial diagnosis of definite hypertension. Alternatively, Korner et al 16 have shown that BP took longer to recover hypertensive levels after withdrawal from prolonged treatment. The normalization of hypertension-induced vascular remodeling obtained after prolonged treatment with some drugs such as ACE inhibitors may explain some cases of sustained remission. Indeed, redevelopment of hypertension was much slower after obtaining regression of both vascular hypertrophy and left ventricular hypertrophy. 16 There appeared to be no dependable way to distinguish in advance Reverters to previous hypertensive BP levels from TABLE 4. EFFECTS OF TRANDOLAPRIL AND PERINDOPRIL ON BLOOD PRESSURE RISE AFTER WITHDRAWAL AMONG RESPONDER PATIENTS Trandolapril (n 35) Perindopril (n 39) P Residual effect after drug discontinuation Residual SBP lowering* (mm Hg) R ratio for SBP (median in %) y (mm Hg) Residual DBP lowering* (mm Hg) R ratio for DBP (median in %) y (mm Hg) Explanatory variables Age (years) NS Male gender (%) Baseline SBP/DBP (mm Hg) / /99 9 NS On-drug evening SBP/DBP lowering (mm Hg) 20 12/ /11 4 NS/.05 On-drug morning SBP/DBP lowering (mm Hg) 14 12/ /6 4.03/.01 On-drug global SBP/DBP lowering (mm Hg) 17 11/ /8 3.03/.007 Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure. * Residual BP lowering, difference between mean baseline BP level and mean post-treatment BP level. R ratio, ratio of residual BP lowering over evening on-drug BP lowering. y, plateau level assessed by exponential modeling.
8 172 VAUR ET AL AJH FEBRUARY 1998 VOL. 11, NO. 2 Nonreverters. However, the likelihood of reversion seemed to increase with the level of the pretreatment BP. 8,17 These studies do not allow us to define the precise time of reversion because BP levels are checked at best monthly. On the contrary, our study was focused on short-term follow-up. To our knowledge, this is the first study addressing the BP course during the few days following withdrawal of chronic antihypertensive therapy. Indeed, the use of home self-measurement of BP allowed us to evaluate individual BP levels twice daily during several consecutive days. Results showed that mean BP rose rapidly to reach a plateau. The level of this plateau was lower than the pretreatment BP level. This could be explained by a regression to the mean phenomenon, placebo effect over time, or persistance of true therapeutic activity. A similar phenomenon has been described previously in a study exploring SMBP during the first 5 days after shortterm administration of enalapril. 18 We decided to focus the individual analysis of reversion on the subgroup of responder patients. Indeed, BP cannot be expected to rise after withdrawing therapy in nonresponders. It appears to be difficult to individualize Reverters from Nonreverters, in that the distribution of the variable (R ratio) exploring reversion is unimodal and continuous. Fifteen percent of patients reverted totally to baseline, whereas BP did not rise at all in 11% of patients. The BP rise in the majority of patients was insufficient to reach baseline BP level. We decided arbitrarily to halve the responder population in Reverters and Nonreverters according to the median of the R ratio. Nonreverters were significantly better controlled during the treatment phase. No other difference between the two groups was found. It means that BP control under therapy is fundamental as far as reversion is considered. The more effective the BP control, the lower the reversion rate. This result may have two medical explanations. First, effective treatment may lead to the resetting of baroreceptors or any other BP control mechanism in well-controlled patients. 6 Second, structural changes may have occurred in previously altered small arteries of such patients, leading to a decrease in peripheral resistances. 19 In the present study, the BP level was consistently higher in the perindopril group than in the trandolapril group during the 6 days after drug cessation. It reverted close to baseline BP level in the perindopril group, whereas about half of the therapeutic effect was still present in the trandolapril group. Two explanations can be put forward. The duration of action of trandolapril is so long that a pharmacologic effect is still present 6 days after withdrawal. This hypothesis is unlikely as far as plasma ACE inhibition is concerned. However, the persistence of some tissue ACE inhibition has been demonstrated in animal models 1 week after cessation. 20 Furthermore, the duration of inhibition of local microvascular ACE in SHR has been shown to be longer with trandolapril than with perindopril. 21 Alternatively, trandolapril administration may have consistently modified BP control mechanisms or structural abnormalities. The BP control was better sustained during therapy in the trandolapril group, particularly in the morning. The well-documented long clinical duration of action of trandolapril supports this hypothesis All drugs will cease to have a pharmacologic action at some time following cessation of therapy. However, it has been suggested that the clinical consequences of drug cessation may be partly drug specific. 17 Withdrawal syndromes have been described in hypertensive patients who abruptly stop taking -blockers. 17,25 The severity of symptoms often depends on whether the patients have ischemic heart disease. Symptoms related to sympathetic overactivity have also been described when -blockers are suddenly stopped. 17 Some authors have studied ambulatory BP monitoring profiles during the 48-h period following cessation of various antihypertensive agents. Reversion occurs within 48 h with some drugs, whereas BP control appears well maintained during this period with others. For example, the magnitude and duration of the BP response over 24 to 48 h was statistically larger after a dose of betaxolol, compared to atenolol 26 ; amlodipine maintained a stable antihypertensive efficacy for 48 h after the dose, whereas BP reverted to baseline BP level 24 h after the last dose of diltiazem. 27 About half of the peak effect was maintained 48 h after withdrawal of trandolapril, whereas the residual effect was only 10% to 20% 48 h after the last dose of enalapril. 22 These discrepancies seem to be related to the duration of action of the drugs as measured by, for instance, their trough-to-peak ratios. The closer to 100% the trough-to-peak ratio, the greater the 48-h post-dose residual effect will be. 28 It would be of great interest to compare the short-term effects of withdrawing agents from various classes exhibiting different durations of action. In responder patients, ACE inhibitor treatment withdrawal is accompanied by a rapid rise in BP (within 48 h), followed by a 4-day BP plateau that is lower than the initial level. The final BP level is variable among patients and may be at least partially determined by the BP-lowering efficacy of the treatment. The better the BP control under therapy, the lower the reversion rate to pretreatment BP level will be. In this respect, the intrinsic properties of the drug may be of some importance. These findings are based on short-term treatment; results could be somewhat different after longer treatment periods.
9 AJH FEBRUARY 1998 VOL. 11, NO. 2 SMBP AND ACE INHIBITOR WITHDRAWAL 173 REFERENCES 1. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335: Dahlöf B, Lindholm LH, Hansson L, et al: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338: SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265: Gong L, Zhang W, Zhu Y, et al: Shangai trial of nifedipine in the elderly (STONE). J Hypertens 1996;14: Hansson L: Cardioprotective potential of antihypertensives. Am J Hypertens 1995;8(suppl):49S 52S. 6. Medical Research Council Working Party on Mild Hypertension: Course of blood pressure in mild hypertensives after withdrawal of long term antihypertensive treatment. Br Med J 1996;293: Burton R: Withdrawing antihypertensive treatment. Hypertension may settle with time. Br Med J 1991;303: Dannenberg AL, Kannel WB: Remission of hypertension. The natural history of blood pressure treatment in the Framingham Study. JAMA 1987;257: Girvin B, Johnston GD: The implication of noncompliance with antihypertensive medication. Drugs 1996;52: Meredith PA: Therapeutic implications of drug holidays. Eur Heart J 1996;17 (suppl A): Mallion JM, Dutrey-Dupagne C, Vaur L, et al: Benefits of electronic pill boxes in evaluating treatment compliance of patients with mild to moderate hypertension. J Hypertens 1996;14: Beltman FW, Heesen WF, Kok RHJ, et al: Predictive value of ambulatory blood pressure shortly after withdrawal of antihypertensive drugs in primary care patients. Br Med J 1996;313: Jamieson MJ, Webster J, Witte K, et al: An evaluation of the A&D UA-751 semi-automated cuff-oscillometric sphygmomanometer. J Hypertens 1990;8: Zannad F, Vaur L, Dutrey-Dupagne C, et al: Assessment of drug efficacy using home self-blood pressure measurement: the SMART study. J Hum Hypertens 1996;10: Maland LJ, Lutz LJ, Castle CH: Effects of withdrawing diuretic therapy on blood pressure in mild hypertension. Hypertension 1983;5: Korner PI, Jennings GL, Esler MD: Pathogenesis of human primary hypertension: a new approach to the identification of causal factors and to therapy. J Hypertens 1986;4 (suppl):s149 S Schobel HP, Schmieder RE, Messerli FH: Risks versus benefits of withdrawing antihypertensive therapy. Drug Safety 1992;7: Chatellier G, Day M, Bobrie G, et al: Feasibility study of N-of-1 trials with blood pressure self-monitoring in hypertension. Hypertension 1995;25: Christensen KL, Jespersen LT, Mulvany MJ: Development of blood pressure in spontaneously hypertensive rats after withdrawal of long-term treatment related to vascular structure. J Hypertens 1989;7: Chevillard C, Brown NL, Jouquey S: Cardiovascular actions and tissue converting enzyme inhibitory effects of chronic enalapril and trandolapril treatment of spontaneously hypertensive rats. J Cardiovasc Pharmacol 1989;14: Vicaut E, Hou X: Duration of inhibition of local microvascular ACE in spontaneously hypertensive rats. J Hypertens 1995;13: Vaur L, Dutrey-Dupagne C, Genès N, et al: Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardiovasc Pharmacol 1995;26: Zannad F, Vaur L, Dutrey-Dupagne C, et al: Antihypertensive effects of trandolapril and nitrendipine in the elderly: a controlled trial with special emphasis on time effect profiles. J Hum Hypertens 1996;10: Cesarone MR, De Sanctis MT, Laurora G, et al: Effects of trandolapril on 24-hour ambulatory blood pressure in patients with mild-to-moderate essential hypertension. J Cardiovasc Pharmacol 1994;23 (suppl 4):S65 S Psaty BM, Koepsell TD, Wagner EH, et al: The relative risk of incident coronary heart disease associated with recently stopping the use of -blockers. JAMA 1990; 263: Johnson BF, Whelton A, McMahon FG: Betaxolol versus atenolol in hypertension: a comparison of efficacy, duration of response and effects of withdrawal (abstr). Am J Hypertens 1990;3(5)part 2:121a. 27. Leenen FHH, Fourney A, Notman G, et al: Persistence of anti-hypertensive effect after missed doses of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol 1986; 41: Meredith P, Elliot HL: Antihypertensive treatment and trough:peak ratio:general considerations. J Hypertens 1994;12(suppl 8):S79 S83.
BP.06). 1.8% 11.7% ( P
AJH 2000;13:184 190 Electronic Pill-Boxes in the Evaluation of Antihypertensive Treatment Compliance: Comparison of Once Daily Versus Twice Daily Regimen Michel Andrejak, Nathalie Genes, Laurent Vaur,
More informationAJH 2000;13: by the American Journal of Hypertension, Ltd /00/$20.00
AJH 2000;13:632 639 Comparison of Three Blood Pressure Measurement Methods for the Evaluation of Two Antihypertensive Drugs: Feasibility, Agreement, and Reproducibility of Blood Pressure Response Stéphanie
More informationThere is convincing evidence in clinical studies
AJH 1998;11:1413 1417 Reliability of Reporting Self-Measured Blood Pressure Values by Hypertensive Patients Thomas Mengden, Rosa Maria Hernandez Medina, Belen Beltran, Elena Alvarez, Karin Kraft, and Hans
More informationOverview of the outcome trials in older patients with isolated systolic hypertension
Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationORIGINAL INVESTIGATION. Is Isolated Home Hypertension as Opposed to Isolated Office Hypertension a Sign of Greater Cardiovascular Risk?
ORIGINAL INVESTIGATION Is Isolated Home as Opposed to Isolated Office a Sign of Greater Cardiovascular Risk? Guillaume Bobrie, MD; Nathalie Genès, MD; Laurent Vaur, MD; Pierre Clerson, MD; Bernard Vaisse,
More informationThe hypertensive effects of the renin-angiotensin
Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring George Bakris, MD A prospective, randomized, open-label, blinded end-point
More informationConcentration-Effect Relationships and Implications for Trough-to-Peak Ratio
AJH 1996;9:66S-70S Concentration-Effect Relationships and Implications for Trough-to-Peak Ratio Peter A. Meredith and Henry L. Elliott The guidelines on trough-to-peak ratio identified an index of the
More informationBRIEF COMMUNICATIONS. KEY WORDS: Ambulatory blood pressure monitoring, placebo effect, antihypertensive drug trials.
AJH 1995; 8:311-315 BRIEF COMMUNICATIONS Lack of Placebo Effect on Ambulatory Blood Pressure Giuseppe Mancia, Stefano Omboni, Gianfranco Parati, Antonella Ravogli, Alessandra Villani, and Alberto Zanchetti
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationLarge therapeutic studies in elderly patients with hypertension
(2002) 16 (Suppl 1), S38 S43 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Large therapeutic studies in elderly patients with hypertension Centro Clinico Profesional
More informationAntihypertensive efficacy of olmesartan compared with other antihypertensive drugs
(2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal
More informationANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION*
Progress in Clinical Medicine 1 ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Keishi ABE** Asian Med. J. 44(2): 83 90, 2001 Abstract: J-MUBA was a large-scale clinical
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More information47 Hypertension in Elderly
47 Hypertension in Elderly YOU DO NOT HEAL OLD AGE; YOU PROTECT IT; YOU PROMOTE IT; YOU EXTEND IT Sir James Sterling Ross Abstract: The prevalence of hypertension rises with age and the complications secondary
More informationAppendix F: Clinical evidence tables
378 Appendix F: F.1 Blood pressure variability STUDY 1 P. M. Rothwell, S. C. Howard, E. Dolan, E. O'Brien, J. E. Dobson, B. Dahlof, N. R. Poulter, and P. S. Sever. Effects of beta blockers and calciumchannel
More informationCalculation of Trough-to-Peak Ratio in the Research Unit Setting
A]H 1996; 9:71S-75S Calculation of Trough-to-Peak Ratio in the Research Unit Setting Advantages and Disadvantages Henry L. Elliott and Peter A. Meredith The trough-to-peak ratio for the response to an
More informationVerapamil SR and trandolapril combination therapy in hypertension a clinical trial of factorial design
Br J Clin Pharmacol 1998; 45: 491 495 Verapamil SR and trandolapril combination therapy in hypertension a clinical trial of factorial design Juergen Scholze, 1 Peter Zilles 2 & Daniele Compagnone 2 on
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationManaging hypertension: a question of STRATHE
(2005) 19, S3 S7 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Managing hypertension: a question of STRATHE Department of Cardiovascular Disease,
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationBlood Pressure Lowering Efficacy of Perindopril/ Indapamide Fixed Dose Combination in Uncontrolled Hypertension
525 Blood Pressure Lowering Efficacy of Perindopril/ Indapamide Fixed Dose Combination in Uncontrolled Hypertension PHIMDA Kriangsak 1* and CHOTNOPARATPAT Paiboon 2 1 Diabetes and Hypertension Clinic,
More informationPhase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018
Phase 3 investigation of aprocitentan for resistant hypertension management Investor Webcast June 2018 The following information contains certain forward-looking statements, relating to the company s business,
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationDrug treatments in hypertension outcome studies
The Second Australian National Blood Pressure Study Page 1 of 6 Background Outcome of treatment of hypertension Over the past 25 years studies of the drug treatment of mild-moderate hypertension have demonstrated
More informationPrognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice
(2005) 19, 801 807 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Prognostic significance of blood pressure measured in the office, at home and
More informationORIGINAL INVESTIGATION. Calcium Antagonists and Mortality Risk in Men and Women With Hypertension in the Framingham Heart Study
ORIGINAL INVESTIGATION s and Mortality Risk in Men and Women With Hypertension in the Framingham Heart Study Vivian M. Abascal, MD; Martin G. Larson, ScD; Jane C. Evans, MPH; Ana T. Blohm, BA; Kim Poli,
More informationHow clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
More informationTrough to peak ratio: current status and applicability
Journal of Human Hypertension (1998) 12, 55 59 1998 Stockton Press. All rights reserved 0950-9240/98 $12.00 REVIEW ARTICLE Trough to peak ratio: current status and applicability Department of Medicine
More informationHypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
More informationIsolated Systolic Hypertension in the elderly. Daniel Hayoz Clinique de Médecine Interne HFR-Hôpital Cantonal Fribourg
Isolated Systolic Hypertension in the elderly Daniel Hayoz Clinique de Médecine Interne HFR-Hôpital Cantonal Fribourg Case no 1 Man aged 75, from Kosovo, in CH since 1.5 years Former smoker (45 PY) BP:
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationWe are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.
Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationMethods DEVICES AND TECHNOLOGY
DEVICES AND TECHNOLOGY Validation of the Omron HEM-907 device for blood pressure measurement Mohamed A. El Assaad, Jirar A. Topouchian, Bernadette M. Darné and Roland G. Asmar Background The aim of this
More informationAngiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with Arterial Hypertension*
The Journal of International Medical Research 2005; 33 (Suppl 1): 21A 29A Angiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with
More informationTHE NEW ARMENIAN MEDICAL JOURNAL DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA)
THE NEW ARMENIAN MEDICAL JOURNAL Vol.5 (2011), Nо 2, p.29-34 DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA) Zelveian P.H. 1, 2, Podosyan G.A. 2 1 Institute
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationCharacteristics and Future Cardiovascular Risk of Patients With Not-At- Goal Hypertension in General Practice in France: The AVANT AGE Study
ORIGINAL PAPER Characteristics and Future Cardiovascular Risk of Patients With Not-At- Goal Hypertension in General Practice in France: The AVANT AGE Study Yi Zhang, MD, PhD; 1 Helene Lelong, MD; 2 Sandrine
More informationCauses of Poor BP control Rates
Goals Of Hypertension Management in Clinical Practice World Hypertension League (WHL) Meeting Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular
More informationValidation of the SEJOY BP-1307 upper arm blood pressure monitor for home. blood pressure monitoring according to the European Society of Hypertension
Validation of the SEJOY BP-1307 upper arm blood pressure monitor for home blood pressure monitoring according to the European Society of Hypertension International Protocol revision 2010 Short title: Validation
More informationEffects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease
European Heart Journal (2003) 24, 475 484 Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease PROGRESS Collaborative Group 1*
More informationDoes masked hypertension exist in healthy volunteers and apparently well-controlled hypertensive patients?
O R I G I N A L A R T I C L E Does masked hypertension exist in healthy volunteers and apparently well-controlled hypertensive patients? I. Aksoy, J. Deinum, J.W.M. Lenders, Th. Thien *# Department of
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationAngiotensin II receptor blockers (ARBs) are the
Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension Suzanne Oparil, MD; 1 David Williams, MD; 2 Steven G. Chrysant, MD, PhD; 3 Thomas C. Marbury,
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More informationShould beta blockers remain first-line drugs for hypertension?
1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,
More informationCitation Acta medica Nagasakiensia. 1997, 42
NAOSITE: Nagasaki University's Ac Title Age and Gender Differences in White Author(s) Li, Zhang Ting Citation Acta medica Nagasakiensia. 1997, 42 Issue Date 1997-12-20 URL http://hdl.handle.net/10069/16086
More informationDIFFERENTE RELAZIONE TRA VALORI PRESSORI E MASSA VENTRICOLARE SX NEI DUE SESSI IN PAZIENTI IPERTESI.
DIFFERENTE RELAZIONE TRA VALORI PRESSORI E MASSA VENTRICOLARE SX NEI DUE SESSI IN PAZIENTI IPERTESI. Franco Cipollini, Carlo Porta, Enrica Arcangeli, Carla Breschi, & Giuseppe Seghieri Azienda USL 3, Ambulatorio
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationHow well do office and exercise blood pressures predict sustained hypertension? A Dundee Step Test Study
(2000) 14, 429 433 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE How well do office and exercise blood pressures predict sustained hypertension?
More informationPrevalence of left ventricular hypertrophy in a hypertensive population
European Heart Journal (1996) 17, 143-149 Prevalence of left ventricular hypertrophy in a hypertensive population J. Tingleff, M. Munch, T. J. Jakobsen, C. Torp-Pedersen, M. E. Olsen, K. H. Jensen, T.
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationEffects of exercise, diet and their combination on blood pressure
(2005) 19, S20 S24 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Effects of exercise, diet and their combination on blood pressure Department
More informationDr Diana R Holdright. MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION.
Dr Diana R Holdright MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION www.drholdright.co.uk Blood pressure is the pressure exerted on the walls of the arteries when the heart pumps;
More informationThe management of hypertension has become
AJH 1997;10:743 749 Additive Effects of Diltiazem and Lisinopril in the Treatment of Elderly Patients With Mild-to-Moderate Hypertension Paul Chan, Chun-Nan Lin, Brian Tomlinson, Tz-Hsin Lin, and Ying-Shiung
More informationANTIHYPERTENSIVE DRUGS USED BY HYPERTENSIVE PATIENTS IN THE PROVINCIAL CITIES OF ISFAHAN, NAJAFABAD AND ARAK
ANTIHYPERTENSIVE DRUGS USED BY HYPERTENSIVE PATIENTS IN THE PROVINCIAL CITIES OF ISFAHAN, NAJAFABAD AND ARAK Keywords Hypertension Adults Antihypertensive drugs Combinational regimens ARYA Journal, 2006,
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationHypertension is a common disease in our
AJH 2000;13:1161 1167 Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on or Trefor O. Morgan, Adrianne Anderson, and Denise Bertram Arthritis and
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationThe effect of a change in ambient temperature on blood pressure in normotensives
(2001) 15, 113 117 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh ORIGINAL ARTICLE The effect of a change in ambient temperature on blood pressure in normotensives
More information9/17/2015. Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14.
0 1 2 Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14. 3 Slide notes: Large trials such as ALLHAT, LIFE and ASCOT show that the majority of patients with hypertension will require multiple
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationEffects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France
Effects of Renin-Angiotensin System blockade on arterial stiffness and function Gérard M. LONDON Manhès Hospital Paris, France Determinants of vascular overload (afterload) on the heart Peripheral Resistance
More informationBlood Pressure Response Under Chronic Antihypertensive Drug Therapy
Journal of the American College of Cardiology Vol. 53, No. 5, 29 29 by the American College of Cardiology Foundation ISSN 735-197/9/$36. Published by Elsevier Inc. doi:1.116/j.jacc.28.9.46 Hypertension
More informationHYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014
HYPERTENSION IN THE ELDERLY A BALANCED APPROACH Barry Goldlist October 31, 2014 DISCLOSURE I have not accepted any money for myself from any pharmaceutical company in the 21 st century I have accepted
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationRisk Factors for Ischemic Stroke: Electrocardiographic Findings
Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead
More information...SELECTED ABSTRACTS...
The following abstracts, from peer-reviewed journals containing literature on vascular compliance and hypertension, were selected for their relevance to this conference and to a managed care perspective.
More informationCombination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London
Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:
More informationΥπέρταση στις γυναίκες
Υπέρταση στις γυναίκες Ελένη Τριανταφυλλίδη Διευθύντρια ΕΣΥ Καρδιολογίας Υπεύθυνη Αντιυπερτασικού Ιατρείου Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο ΑΤΤΙΚΟΝ Cardiovascular disease is the Europe
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationStroke A Journal of Cerebral Circulation
Stroke A Journal of Cerebral Circulation JULY-AUGUST VOL. 7 1976 NO. 4 Components of Blood Pressure and Risk of Atherothrombotic Brain Infarction: The Framingham Study WILLIAM B. KANNEL, M.D., THOMAS R.
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationShort-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: A meta-analysis
ORIGINAL ARTICLE Cardiology Journal 2010, Vol. 17, No. X, pp. 1 XX Copyright 2010 Via Medica ISSN 1897 5593 Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients:
More informationDRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU
Original Article DRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU V.Gowri 1, K.Punnagai, K.Vijaybabu 3, Dr.Darling Chellathai 4 1 Assistant Professor
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationSYNOPSIS. Publications No publications at the time of writing this report.
Drug product: TOPROL-XL Drug substance(s): Metoprolol succinate Study code: D4020C00033 (307A) Date: 8 February 2006 SYNOPSIS Dose Ranging, Safety and Tolerability of TOPROL-XL (metoprolol succinate) Extended-release
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationRationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC
Rationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC Seung Woo Park, MD Samsung Medical Center BP Control Rates in Asia BP controlled BP uncontrolled 24.3% 36.6% 19% Turkey
More information& Wilkins. a Division of Cardiology, Schulich Heart Centre, b Institute for Clinical and
Original article 333 Optimum frequency of office blood pressure measurement using an automated sphygmomanometer Martin G. Myers a, Miguel Valdivieso a and Alexander Kiss b,c Objective To determine the
More informationCentral Pressures and Prehypertension
Central Pressures and Prehypertension Charalambos Vlachopoulos Associate Professor of Cardiology 1 st Cardiology Dept Athens Medical School Central Pressures and Prehypertension Charalambos Vlachopoulos
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationUnderstanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?
Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,
More informationPrimary hypertension in adults
Primary hypertension in adults NICE provided the content for this booklet which is independent of any company or product advertised Hypertension Welcome NICE published an updated guideline on the diagnosis
More informationInhibitory Effects of Azelnidipine Tablets on Morning Hypertension
Drugs R D (2013) 13:63 73 DOI 10.1007/s40268-013-0006-8 ORIGINAL RESEARCH ARTICLE Inhibitory Effects of Azelnidipine Tablets on Morning Hypertension Kazuomi Kario Yuki Sato Masayuki Shirayama Megumi Takahashi
More information